Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated October 13, 2023, serves as a transaction notification for the month of October 2023. The document discloses share acquisitions by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them (PCAs) under the Company's Share Reward Plan.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, or debt metrics. It exclusively reports on specific share transactions executed on October 12, 2023, on the London Stock Exchange (XLON).
| Transaction Type | Instrument | Price (GBP) | Total Volume |
|---|---|---|---|
| Acquisition (Dividend Re-investment) | Ordinary Shares (31 1/2 pence each) | £15.2080 | 228 |
| Acquisition (Dividend Re-investment) | Ordinary Shares (31 1/2 pence each) | £15.2473 | 924 |
Note: The total volume of 1,152 shares represents the sum of individual transactions listed in the filing. The primary price observed was £15.2080, with a secondary price of £15.2473 for specific transactions.
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. It strictly documents routine compliance disclosures regarding insider shareholdings resulting from dividend re-investment.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. The transactions were executed automatically following the re-investment of dividends paid to shareholders on October 12, 2023.
Key Facts for Investor Verification
- Transaction Nature: All reported transactions were acquisitions of Ordinary Shares via dividend re-investment, not open market purchases or sales.
- Participants: Transactions involved 11 individuals, including CEO Emma Walmsley, Chief People Officer Diana Conrad, and Company Secretary Victoria Whyte (and her PCA).
- Share Price: The share price at the time of transaction was approximately £15.21.
- Scope: This filing is a regulatory disclosure of insider holdings and does not reflect the company's overall financial performance for the period.